MedTech, Tools & Diagnostic Summit
- May 26, 2021
The MedTech and Diagnostics space is extremely active currently as companies continue to develop innovative technologies to treat and deliver medicine to patients. Please join us at our MedTech, Tools & Diagnostic Summit on May 26 featuring over 30 leading companies in the MedTech & Diagnostic spaces. We are also hosting three industry & KOL panels discussing leading trends in the MedTech space – for more details on each of the panels please see the descriptions below.
To access information for the MedTech Day Tools & Diagnostic Summit , please enter your password. Your password can be found in the email invitation that was sent to you.
Log In For Details
In this panel, two pre-eminent thought leaders on either sides of the Atlantic share with us their insights on the challenges and opportunities in the TMVR landscape.
Moderator: Suraj Kalia, Managing Director
Senior Analyst for MedTech
Oppenheimer & Co. Inc.
Comps: ABT, EW, MDT, BSX
Speaker: Dr. Paul Sorajja
Interventional Cardiology Specialist
Minneapolis Heart Institute at Abbott Northwestern Hospital
Dr. Paul Sorajja is an Interventional Cardiology Specialist affiliated with Minneapolis Heart Institute at Abbott Northwestern Hospital. He was previously a professor of medicine at the Mayo Clinic, where he also completed his residency. Dr. Sorajja has authored over 100 publications. Dr. Sorajja is a fellow of the American College of Cardiology, and American Heart Association. His specialties includes: structural heart interventions such as TAVR, paravalvular leak repair, and balloon valvuloplasty amongst others.
Speaker: Dr. Stephan von Bardeleben
Head of the Department for Structural Heart Disease and Interventional Heart Valve Therapy
Mainz University of Medicine
Dr. Stephan von Bardeleben is the head of the Department for Structural Heart Disease and Interventional Heart Valve Therapy at Mainz University of Medicine in Germany. His department is one of the leading worldwide centers in Mitral and Tricuspid valve interventions, and has participated in a number of early clinical trials for these types of treatments. He was the previous president of the group Echocardiography of the German Society of Cardiology. Dr. von Bardeleben is the co-editor-in-chief for the Echocardiography journal, as well as a reviewer for several others.
Our diabetes panel will offer two unique perspectives on the future of diabetes devices, from basic science to patients’ responses to new technology. With a rapidly expanding and evolving reach of diabetes devices, we believe these insights will be highly valuable. In addition to her active patient clinic, Professor Tracey McLaughlin, MD, MS, conducts extensive clinical research related to insulin resistance, diabetes, obesity and cardiovascular disease. Dr. McLaughlin’s research program over the past 18 years has made important contributions to the understanding of the relationship been obesity and insulin resistance. Kelly Close has started multiple organizations which keep their finger on the pulse of technology advancements in diabetes and patient as well as physician views on these new technologies. Kelly is the President of Close Concerns, Inc. and the founder of The diatribe Foundation, a nonprofit established in 2013 to improve the lives of people with diabetes and pre-diabetes and to advocate for action.
Moderator: Steve LichtmanManaging Director, Senior Analyst for MedTech
Oppenheimer & Co. Inc.
Comps: ABT, DXCM, MDT, MNKD, NMRD, PODD, SENS, TNDM
Speaker: Dr. Tracey McLaughlinProfessor of Medicine, Division of Endocrinology
at the Stanford University School of Medicine
Dr. Tracey McLaughlin is a Professor of Medicine, Division of Endocrinology, at the Stanford University School of Medicine. Dr. McLaughlin conducts clinical research related to obesity, insulin resistance, diabetes, and cardiovascular disease (CVD). She also maintains an active clinic for patients with complicated type 1, type 2, or other forms of diabetes, polycystic ovarian disease, and hypoglcyemia. Dr. McLaughlin has over 100 publications in peer-reviewed journals and is founder of the Diabetes Task Force at Stanford Hospital.
Founder, The diatribe Foundation; President, Close Concerns, Inc.
Speaker: Kelly Close
Kelly Close founded Close Concerns in 2002; Kelly and her team write extensively on diabetes, pre-diabetes, obesity, and digital health for Closer Look, a highly-praised subscription news service which keeps researchers and members of industry abreast of scientific breakthroughs and market dynamics. Kelly also is founder of diaTribe, an education resource which informs patients and caregivers of the latest products and research in diabetes. Kelly is an associate editor of Clinical Diabetes, a journal focused on diabetes for primary care physicians published quarterly by the ADA. Kelly also chairs The diaTribe Foundation, a nonprofit established in 2013 to improve the lives of people with diabetes and pre-diabetes and to advocate for action. Kelly's passion for the field comes from her extensive professional work as well as from her personal experience, having had diabetes for nearly 35 years. Kelly is the author of over 35 peer-reviewed manuscripts as well as “Targeting A Cure for Type 1 Diabetes: How Long Do We Have to Wait?” an award-winning book published by the ADA in 2013.
Moderator: Louis A. Cannon, MDFounder SR Mg Director the BioStar Funds, Founder, President
The Cardiac & Vascular Research Center of N. Michigan
Louis Cannon, MD, a former Judith Volkman Scholar in Residence, is the President of the Cardiac and Vascular Research Center of Northern Michigan. Dr. Cannon has been repeatedly honored as one of "America’s Top Interventional Cardiologists” and has authored hundreds of articles for medical publications and holds a vast number of medical device patents in the United States. Currently, he is a member of the Board of Directors of CardioVascular Ingenuity and Kona. Previously, he has served on the strategic advisory boards for Fortune 500 companies such as Medtronic, Abbott, Boston Scientific, Johnson and Johnson, and Covidien, as well as many early developing medical technology companies. Dr. Cannon, through BioStar Ventures, has participated in the start-up and subsequent development of a multitude of developing bio-technological, or emerging healthcare companies, and has served as the National or International Principal Investigator for landmark cardiovascular studies. Additionally, he was Chairman of the Board of AorTx, Inc., which was successfully acquired by a publicly traded company. Similarly, as BioStar was the lead investor of Setagon, later acquired by a Fortune 100 company, Dr. Cannon served as the Chairman of the Scientific Advisory Board. In 2007, Dr. Cannon assisted in performing First-In-Man percutaneous Aortic Valve procedures in Paraguay.
Speaker: Ken CharhutExecutive Chairman FOLDAX, former CEO MindFrame
Founder and former CEO of Compellon
Ken brings more than thirty years of medical device experience to Foldax. Currently, he leads two medical device and technology companies. He is executive chairman of the board at Foldax and chairman of the board for Compellon, a bioinformatics company. Previously, Ken held board and CEO roles at Reshape Medical a private device company which commercialized products to treat obesity that was acquired by EnteroMedics in 2017. He was President and CEO of MindFrame, Inc. which makes devices to treat ischemic strokes. In July 2012, Covidien, the world leader in that market, acquired MindFrame. Earlier, Ken was CEO and President of Orqis Medical, privately funded company in the congestive heart failure space. Ken raised over $85 million for the company and took if from concept through IDE clinical trials. Prior to Orqis, Ken spent 16 years in general management position with Baxter Healthcare corporation, including President of the Bentley Division and President of New Business Initiatives for the Cardiovascular Surgery Division. He also spent four years in Japan as Managing Director of Baxter Japan Cardiovascular Division. Ken earned his B.S.ME degree from Cornell University and his M.B.A. from the University of Chicago Booth School of Business and completed the manufacturing management program at General Electric Company.
Speaker: Mark TolandCEO, MMI MicroSurgical Robotics, former CEO of Corindus Vascular Robotics
Mark Toland is the CEO of MMI SpA. Before joining MMI, Mark served as the President and CEO of Corindus where he transformed the company into the industry leader in vascular robotics with the only approved system for coronary, peripheral and neurovascular indications. The Siemens Healthineers acquisition of Corindus for $1.1 billion was the fifth largest medical technology acquisition of 2019. Prior to Corindus, Mark served as Senior Vice President of Boston Scientific, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, which represented approximately $4 billion in revenue. Mark brings over 25 years of medical device experience to MMI. In addition, he serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an Intravascular Lithotripsy company. He also serves as a partner and EIR at Biostar Capital, a healthcare focused Venture Capital firm. Mr. Toland holds a Bachelor of Science in Business Administration from the University of Louisville.
Speaker: Ray Turner, MDNeurosurgeon and Endovascular Surgeon; TeleRobotics Treating Strokes Robotically: access to care imperative
Ray Turner is currently Professor Surgery and an Endovascular Neurosurgeon. He is also Chief Medical Officer for Neurovascular and Robotics at Siemens Healthineers. He was also previously a Professor in the Department of Neurosurgery at the Medical University of South Carolina. He hold a B.S. from Sacred Heart University and a M.D. from Karol Marcinkowski University of Medical Sciences in Poland.